Arvinas ARVN
NASDAQ ARVN
$7.43 -0.31 (-3.94%)
At close: Oct 1, 2026 · 4:00 PM EDT

Arvinas (ARVN) Liabilities and Shareholders Equity (2017 - 2026)

Updated

Arvinas' Liabilities and Shareholders Equity came in at $675.1 million for Q2 2026, down 25.8% from $909.3 million a year earlier but up 4.3% from the prior quarter.

Analysis

Arvinas (ARVN) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends

At the end of FY2025, Arvinas' Liabilities and Shareholders Equity was $717.9 million, down 34.2% from FY2024.

  • Liabilities and Shareholders Equity carries a five-year compound annual growth rate of 0.0% (FY2020 to FY2025).
  • Going back by year, Liabilities and Shareholders Equity was $1.09 billion in FY2024 (-16.3%), $1.3 billion in FY2023 (+2.8%), $1.27 billion in FY2022 (-19.8%) and $1.58 billion in FY2021 (+120.5%).
  • The five-year range for quarterly Liabilities and Shareholders Equity is $647.5 million (Q1 2026) to $1.6 billion (Q3 2021).
  • Year-over-year, Liabilities and Shareholders Equity has declined for seven consecutive quarters, with an average decline of 21.9% over the last eight quarters.
  • The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in Q3 2021 (growth of 490.1%), and the weakest in Q1 2026 (a decline of 35.3%).
  • Business Quant data shows ARVN's Liabilities and Shareholders Equity at $647.5 million (Q1 2026), $717.9 million (Q4 2025) and $844.3 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Arvinas 505.42 Mn -2.15 Bn - 675.10 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 675.10 Mn
Mar 31, 2026 647.50 Mn
Dec 31, 2025 717.90 Mn
Sep 30, 2025 844.30 Mn
Jun 30, 2025 909.30 Mn
Mar 31, 2025 1.00 Bn
Dec 31, 2024 1.09 Bn
Sep 30, 2024 1.17 Bn
Jun 30, 2024 1.28 Bn
Mar 31, 2024 1.21 Bn
Dec 31, 2023 1.30 Bn
Sep 30, 2023 1.06 Bn
Jun 30, 2023 1.08 Bn
Mar 31, 2023 1.18 Bn
Dec 31, 2022 1.27 Bn
Sep 30, 2022 1.33 Bn
Jun 30, 2022 1.41 Bn
Mar 31, 2022 1.49 Bn
Dec 31, 2021 1.58 Bn
Sep 30, 2021 1.60 Bn
API Access

Arvinas Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ARVN&period=max&api_key=YOUR_API_KEY